A submission to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of a previously approved branded drug. This application relies on the safety and efficacy findings of the original drug.
Meet us at CPHI Milan 2026, Booth No. 10H33, Oct 6-8, Fiera Milano, Italy Schedule a Meeting
A submission to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of a previously approved branded drug. This application relies on the safety and efficacy findings of the original drug.
Explore how Neuland supports API programs from pre-IND through commercial manufacturing.